Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says

MT Newswires Live10-17 00:01

Sarepta Therapeutics (SRPT) faces new growth opportunity emerging from siRNA programs, with near-term investor focus to likely remain on the duchenne muscular dystrophy franchise, Wedbush said in a Friday note.

Wedbush further said that the company's preclinical data and partner Arrowhead Pharmaceuticals' (ARWR) initial phase 1 data provide encouraging evidence supporting potential of SPR-1003 in myotonic dystrophy type 1 and SRP-1005 in Huntington's disease.

Recent SPR-1003 preclinical data showed "robust" reduction of dystrophia myotonica protein kinase expression in not only cytoplasm but also in nucleus, the firm noted.

Additionally, SRP-1005 data showed that subcutaneously injected siRNA leads to higher target knockdown in two critical deep brain structures compared with intrathecal delivery, Wedbush further said.

Wedbush maintained its outperform rating on the stock with $35 per share price target.

Price: 17.28, Change: -0.51, Percent Change: -2.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment